PLIANT THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 11, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: March 11, 2026
| PLIANT THERAPEUTICS, INC. | ||
| By: | /s/ Bernard Coulie | |
|---|---|---|
| Bernard Coulie, M.D., Ph.D. | ||
| President and Chief Executive Officer | ||
| By: | /s/ Keith Cummings | |
| Keith Cummings, M.D., M.B.A. | ||
| Chief Financial Officer | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints, Bernard Coulie and Keith Cummings and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and either of them, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Bernard Coulie | President, Chief Executive Officer and Director | March 11, 2026 |
| Bernard Coulie, M.D., Ph.D. | Principal Executive Officer | |
| /s/ Keith Cummings | Chief Financial Officer | March 11, 2026 |
| Keith Cummings, M.D., M.B.A. | Principal Financial Officer | |
| /s/ Hoyoung Huh | Chairman of the Board, Director | March 11, 2026 |
| Hoyoung Huh, M.D., Ph.D. | ||
| /s/ Suzanne Bruhn | Director | March 11, 2026 |
| Suzanne Bruhn, Ph.D. | ||
| /s/ Darren Cline | Director | March 11, 2026 |
| Darren Cline, M.B.A. | ||
| /s/ David Pyott | Director | March 11, 2026 |
| David Pyott, M.A, M.B.A. | ||
| /s/ Gayle Crowell | Director | March 11, 2026 |
| Gayle Crowell | ||
| /s/ John Curnutte | Director | March 11, 2026 |
| John Curnutte, M.D., Ph.D | ||
| /s/ Katharine Knobil | Director | March 11, 2026 |
| Katharine Knobil, M.D. | ||
| /s/ Thomas McCourt | Director | March 11, 2026 |
| Thomas McCourt | ||
| /s/Steve Krognes | Director | March 11, 2026 |
| Steve Krognes, M.B.A. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.